No Data
No Data
$FATE Stock Is up 12% Today. Here's What We See in Our Data.
Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall
Fate Therapeutics Receives RMAT Designation From FDA for FT819
Express News | Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (Sle)
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?